Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

MonumenTAL-6

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

  • NCT06208150 ↗
  • Active, not recruiting
  • Janssen Research & Development, LLC
  • Deep

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Preliminary discovery

Commentary in our index that names this trial so far

Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.

ChannelFound
X threads20
YouTube11
Podcasts6
Bluesky threads3

The trial

ClinicalTrials.gov
Official title
64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom
Phase
Phase 3
Status
Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Talquetamab; Pomalidomide; Teclistamab; Elotuzumab; Dexamethasone; Bortezomib
Arms
  • Arm A: Talquetamab + Pomalidomide (Tal-P) · Experimental
  • Arm B: Talquetamab + Teclistamab (Tal-Tec) · Experimental
  • Arm C: Elotuzumab+ Pomalidomide+Dexamethasone (EPd) or Pomalidomide+Bortezomib+Dexamethasone (PVd) · Active comparator
Enrollment
838
Primary outcomes
  • Progression Free Survival (PFS)
Sponsor
Janssen Research & Development, LLC
Start
Jan 22, 2024
Primary completion
Apr 1, 2026
Results posted
No
Registry record
NCT06208150 · updated Sep 25, 2026